354 related articles for article (PubMed ID: 23533225)
1. Clinical relevance of combined FSH and AMH observations in infertile women.
Gleicher N; Kim A; Kushnir V; Weghofer A; Shohat-Tal A; Lazzaroni E; Lee HJ; Barad DH
J Clin Endocrinol Metab; 2013 May; 98(5):2136-45. PubMed ID: 23533225
[TBL] [Abstract][Full Text] [Related]
2. Toward a better understanding of functional ovarian reserve: AMH (AMHo) and FSH (FSHo) hormone ratios per retrieved oocyte.
Gleicher N; Kim A; Weghofer A; Barad DH
J Clin Endocrinol Metab; 2012 Mar; 97(3):995-1004. PubMed ID: 22170712
[TBL] [Abstract][Full Text] [Related]
3. Diminished ovarian reserve is not observed in infertility patients with high normal CGG repeats on the fragile X mental retardation 1 (FMR1) gene.
Schufreider A; McQueen DB; Lee SM; Allon R; Uhler ML; Davie J; Feinberg EC
Hum Reprod; 2015 Nov; 30(11):2686-92. PubMed ID: 26345686
[TBL] [Abstract][Full Text] [Related]
4. Use of ovarian reserve parameters for predicting live births in women undergoing in vitro fertilization.
Lukaszuk K; Kunicki M; Liss J; Lukaszuk M; Jakiel G
Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):173-7. PubMed ID: 23485092
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of premature ovarian senescence: I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Müllerian hormone.
Gleicher N; Weghofer A; Barad DH
Fertil Steril; 2009 May; 91(5):1700-6. PubMed ID: 18384775
[TBL] [Abstract][Full Text] [Related]
6. Correlation of triple repeats on the FMR1 (fragile X) gene to ovarian reserve: a new infertility test?
Gleicher N; Weghofer A; Oktay K; Barad DH
Acta Obstet Gynecol Scand; 2009; 88(9):1024-30. PubMed ID: 19642041
[TBL] [Abstract][Full Text] [Related]
7. Differences in ovarian aging patterns between races are associated with ovarian genotypes and sub-genotypes of the FMR1 gene.
Gleicher N; Kim A; Weghofer A; Barad DH
Reprod Biol Endocrinol; 2012 Sep; 10():77. PubMed ID: 22963248
[TBL] [Abstract][Full Text] [Related]
8. [Low circulating anti-Müllerian hormone and normal follicle stimulating hormone levels: which prognosis in an IVF program?].
Grzegorczyk-Martin V; Khrouf M; Bringer-Deutsch S; Mayenga JM; Kulski O; Cohen-Bacrie P; Benaim JL; Belaisch-Allart J
Gynecol Obstet Fertil; 2012; 40(7-8):411-8. PubMed ID: 22521986
[TBL] [Abstract][Full Text] [Related]
9. Utility of age-specific serum anti-Müllerian hormone concentrations.
Barad DH; Weghofer A; Gleicher N
Reprod Biomed Online; 2011 Mar; 22(3):284-91. PubMed ID: 21269880
[TBL] [Abstract][Full Text] [Related]
10. Discordances between follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) in female infertility.
Gleicher N; Weghofer A; Barad DH
Reprod Biol Endocrinol; 2010 Jun; 8():64. PubMed ID: 20565808
[TBL] [Abstract][Full Text] [Related]
11. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients.
Arce JC; La Marca A; Mirner Klein B; Nyboe Andersen A; Fleming R
Fertil Steril; 2013 May; 99(6):1644-53. PubMed ID: 23394782
[TBL] [Abstract][Full Text] [Related]
12. Age at menarche: a predictor of diminished ovarian function?
Weghofer A; Kim A; Barad DH; Gleicher N
Fertil Steril; 2013 Oct; 100(4):1039-43. PubMed ID: 23809497
[TBL] [Abstract][Full Text] [Related]
13. Starting and resulting testosterone levels after androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR).
Gleicher N; Kim A; Weghofer A; Shohat-Tal A; Lazzaroni E; Lee HJ; Barad DH
J Assist Reprod Genet; 2013 Jan; 30(1):49-62. PubMed ID: 23212832
[TBL] [Abstract][Full Text] [Related]
14. How FSH and AMH reflect probabilities of oocyte numbers in poor prognosis patients with small oocyte yields.
Gleicher N; Darmon SK; Kushnir VA; Weghofer A; Wang Q; Zhang L; Albertini DF; Barad DH
Endocrine; 2016 Nov; 54(2):476-483. PubMed ID: 27510172
[TBL] [Abstract][Full Text] [Related]
15. The relationship between the number of CGG repeats and serum level of anti-Müllerian hormone in women without FMR1 premutation.
Choe SA; Kim KC; Lee JY; Kim CH; Hwang D; Jee BC
Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(2):275-8. PubMed ID: 23731704
[TBL] [Abstract][Full Text] [Related]
16. The impact of androgen metabolism and FMR1 genotypes on pregnancy potential in women with dehydroepiandrosterone (DHEA) supplementation.
Weghofer A; Kim A; Barad DH; Gleicher N
Hum Reprod; 2012 Nov; 27(11):3287-93. PubMed ID: 22811313
[TBL] [Abstract][Full Text] [Related]
17. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
[TBL] [Abstract][Full Text] [Related]
18. Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study.
Papaleo E; Zaffagnini S; Munaretto M; Vanni VS; Rebonato G; Grisendi V; Di Paola R; La Marca A
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():94-99. PubMed ID: 27835829
[TBL] [Abstract][Full Text] [Related]
19. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
[TBL] [Abstract][Full Text] [Related]
20. Maternal serum concentration of anti-Müllerian hormone is a better predictor than basal follicle stimulating hormone of successful blastocysts development during IVF treatment.
Sadruddin S; Barnett B; Ku L; Havemann D; Mucowski S; Herrington R; Burggren W
PLoS One; 2020; 15(10):e0239779. PubMed ID: 33044971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
